EP0042 – New Clinical Study for MDS Patients

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed in our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.


  1. SUB-TYPE OF MDS: Patients with MDS or CMML who have relapsed from or are refractory to previous therapy
  2. SEVERITY OF MDS: Intermediate, High or Very High Risk
  3. NAME OF DRUG: EP0042
  4. Aims and benefits: This Phase I/IIa study investigates different doses of the drug EP0042 to determine the dose which is safe, well tolerated and effective.
  5. Primary outcome: To identify toxicities that occur due to dosage of the study drug.

  1. Basic inclusion criteria:
    • MDS or CMML patients who have relapsed from or are refractory to previous therapy.
    • ECOG of ≤ 2
  2. Basic exclusion criteria:
    • Evidence of disease spread to the brain
    • Malignant disease other than that being treated in the study
    • Transplantation within the last 90 days or active immunosuppression for graft versus host disease
  3. Trial sites/locations and name of physician in charge of trial (none are currently recruiting):
    • Dr David Taussig, London, UK, United Kingdom

If you think this information is relevant to you, please discuss it with your own physician.

Free donations by shopping